XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Collaborative Arrangements and Licensing Agreements (Tables)
 9 Months Ended
Sep. 30, 2024
AstraZeneca [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2024 and 2023, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):

 
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
  
   
2024
    
2023
    
2024
    
2023
  
Revenue from our relationship with AstraZeneca
  
$
19,461
    
$
15,959
    
$
47,106
    
$
99,885
  
Percentage of total revenue
    
15
%
    
11
%
    
10
%
    
22
%
Biogen [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2024 and 2023, we earned the following revenue from our relationship with Biogen (in thousands, except percentage amounts):

 
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
  
   
2024
    
2023
    
2024
    
2023
  
Revenue from our relationship with Biogen
  
$
80,291
    
$
94,695
    
$
277,686
    
$
262,599
  
Percentage of total revenue
    
60
%
    
66
%
    
58
%
    
57
%
Otsuka [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2024 and 2023, we earned the following revenue from our relationship with Otsuka (in thousands, except percentage amounts):

 
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
  
   
2024
    
2023
    
2024
    
2023
  
Revenue from our relationship with Otsuka
  
$
1,083
    
$
—
    
$
20,773
    
$
—
  
Percentage of total revenue
    
1
%
    
0
%
    
4
%
    
0
%
Roche [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2024 and 2023, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):

   
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
  
   
2024
    
2023
    
2024
    
2023
  
Revenue from our relationship with Roche
  
$
11,084
    
$
8,858
    
$
33,679
    
$
16,979
  
Percentage of total revenue
    
8
%
    
6
%
    
7
%
    
4
%